Clinical Trials Directory

Trials / Completed

CompletedNCT01578304

Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder

Phase IV Study to Evaluate the Efficacy and Safety Imidafenacin Versus Fesoterodine in Patients With Overactive Bladder

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
207 (actual)
Sponsor
LG Life Sciences · Industry
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

To evaluate the efficacy and safety after 12 weeks oral administration of Imidafenacin 0.1mg b.i.d versus Fesoterodine 4mg once daily for the urge incontinence and/or increased urinary frequency associated with urgency as may occur in patients with overactive bladder.

Conditions

Interventions

TypeNameDescription
DRUGImidafenacinTablet, 12 weeks twice daily
DRUGFesoterodineTablet, 12 weeks once daily

Timeline

Start date
2010-12-01
Primary completion
2011-10-01
Completion
2011-10-01
First posted
2012-04-16
Last updated
2012-04-16

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01578304. Inclusion in this directory is not an endorsement.